Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–308 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tenofovir Disoproxil Fumarate Clear all

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 55
States / cities: Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more

Conditions: Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions: PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, EFV/FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: HIV Infections
Interventions: TRUVADA + Raltegravir; Drug
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Combination Therapy
Interventions: Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: HIV Prevention
Interventions: Immediate Intervention Arm, Deferred Intervention Arm; Drug
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: PrEP Adherence Monitoring
Interventions: Truvada; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 54
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more

Conditions: HIV Infections
Interventions: Kaletra + Isentress, Atripla; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 3 more

Conditions: HIV Infections
Interventions: Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine, tenofovir disproxil fumarate/emtricitabine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: HIV Prevention, Transgender Health
Interventions: 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
Interventions: TMC278, Efavirenz; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more

Conditions: Healthy, HIV
Interventions: Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR); Drug
Lead sponsor: Marla Keller; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Chronic Hepatitis B
Interventions: Tenofovir disoproxil fumarate, GS-4774; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: Palo Alto, California • Sacramento, California • San Diego, California + 9 more

Conditions: Chronic Hepatitis B
Interventions: TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more

Conditions: HIV Infections
Interventions: Single dose of Genvoya® and a single 800 mg dose of Darunavir®; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infection
Interventions: emtricitabine/tenofovir, abacavir/lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: HIV
Interventions: Truvada, Gel lubricant; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Decatur, Georgia

Search by objective public record fields.

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

ANCHORS Alcohol & Sexual Health Study: UH3 Project

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Pre-Exposure Prophylaxis for Transgender Women in the US and South America

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV